Back
ESC Professional Premium Access

Heart failure with improved ejection fraction (HFimpEF) in patients treated with sacubitril/valsartan (SV)

Session: Heart failure pharmacotherapy - Sacubitril/valsartan
Topic: Pharmacotherapy
Speaker: Doctor K. Lee (Seoul, KR)
Event: ESC Congress 2022

Congress Presentation

About the speaker

Doctor Kwan Yong Lee

Seoul St. Mary's Hospital, Seoul (Korea (Republic of))
0 follower

7 more presentations in this session

Haemodynamic forces as predictors of cardiac remodelling and outcome in heart failure with reduced ejection fraction treated with sacubitril/valsartan

Speaker: Assistant Professor A. Giannoni (Pisa, IT)

Access
Abstract
Slides
Thumbnail

Maximum dose sacubitril/valsartan in heart failure with reduced ejection fraction: does atrial fibrillation compromise the benefits?

Speaker: Doctor G. Oliveira Campos (Coimbra, PT)

Access
Abstract
Slides
Thumbnail

Efficacy and safety of sacubitril valsartan in heart failure compared to renin angiotensin aldosterone system inhibitors: a systematic review and meta analysis of randomised controlled trials

Speaker: Professor A. Bielecka-Dabrowa (Lodz, PL)

Access
Abstract
Slides
Thumbnail

Effects of sacubitril valsartan on renal function in adults with heart failure: a systematic review and meta analysis of randomised controlled trials

Speaker: Professor A. Hernandez (Storrs, US)

Access
Abstract
Slides
Thumbnail

Comparative effectiveness of sacubitril/valsartan versus angiotensin converting enzyme inhibitors/angiotensin receptor blockers in de novo heart failure patients

Speaker: Doctor H. Schwende (Basel, CH)

Access
Abstract
Slides
Thumbnail

Access the full session

Heart failure pharmacotherapy - Sacubitril/valsartan

Speakers: Doctor K. Lee, Assistant Professor A. Giannoni, Doctor G. Oliveira Campos, Professor A. Bielecka-Dabrowa, Professor A. Hernandez...
Access
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb